SCHEMBL375299

SCHEMBL375299

COC(=O)c1cccc(-c2cc(CN(C(=O)c3ncn(C)n3)C3CCOCC3)ccc2F)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.38
SLC6A9 P48067 8/20 0.38
KCNH2 Q12809 7/20 0.38
SLC6A5 Q9Y345 5/20 0.38
WDR5 P61964 3/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
UBE2M P61081 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.36
CYP3A4 P08684 2/20 0.36
CHRM3 P20309 1/20 0.35
PRKDC P78527 1/20 0.35
MGLL Q99685 1/20 0.35
PARP1 P09874 1/20 0.35
PIK3CD O00329 1/20 0.35
CYP2D6 P10635 2/20 0.35
ERN1 O75460 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4545279 0.92 PDE4D (0.40) SLC6A9KCNH2SLC6A5NPC1RAB9A
SCHEMBL374972 0.88 SLC6A9 (0.40) SLC6A9KCNH2SLC6A5WDR5CYP3A4
SCHEMBL15116033 0.84 PIK3CA (0.38) SLC6A9KCNH2SLC6A5CYP3A4PIK3CD
SCHEMBL1050669 0.82 MGLL (0.40) CSF1RWDR5NPC1RAB9AMGLL
SCHEMBL15116036 0.81 SLC6A9 (0.36) SLC6A9KCNH2SLC6A5CYP3A4CYP2D6
SCHEMBL15104641 0.80 SLC6A9 (0.40) SLC6A9KCNH2SLC6A5CYP3A4CYP2D6
SCHEMBL4545282 0.80 SLC6A9 (0.39) SLC6A9KCNH2SLC6A5CYP3A4CHRM3
SCHEMBL15104512 0.78 SLC6A9 (0.44) SLC6A9KCNH2SLC6A5PIK3CD
SCHEMBL374984 0.77 SLC6A9 (0.55) SLC6A9KCNH2SLC6A5UBE2MDCUN1D1
SCHEMBL15104501 0.76 SLC6A9 (0.41) SLC6A9KCNH2SLC6A5CYP3A4MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 EP disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES SLC18A2, SLC1A2, SLC6A1 CSF1R 3245/4885SLC6A9 8/4885KCNH2 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.